Pegademase is a modified form of bovine adenosine deaminase used to treat adenosine deaminase deficiency, a condition which leads to the formation of adenosine metabolites which are cytotoxic to lymphocytes. Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.
- Mechanism
- Curator reviewed
Pegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination.
- Primary indication
- For treatment of adenosine deaminase deficiencyCurator reviewed · 1 structured indication
- Formula / weight
- C1821H2834N484O552S14 · 40788.2 Da
- First approval
- United States, 2010
- Also known as
- PEG-adenosine deaminase · pegADA · Pegademase bovine
Resolves to
Clinical / RWD
Targets
What you can answer from here — as of July 17, 2026
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Pegademase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account